Ï Aí. åîïìïëïãåßôáé...

Boy ¼ôáí Ýìáèá üôé ìïëýíèçêá ìå ôïí éü ôïõ AIDS, Ýíéùóá üôé âñÝèçêá óôï áðüëõôï êåíü.

Ãéá áñêåôü êáéñü Ýæçóá áëëÜ óôçí ðñáãìáôéêüôçôá äåí æïýóá. ÁðëÜ õðÞñ÷á.
Äåí Ýíéùóá ïýôå ðüíï, ïýôå èëßøç.
Åßðá óôïí åáõôü ìïõ: "Áò ðñüóå÷á".

ÌåãÜëùóá óå ìéá åðï÷Þ ðïõ áõôïß ðïõ Ýðñåðå íá êÜíïõí óõíÝ÷åéá êáìðÜíéåò êáôÜ ôïõ éïý ìïßñáæáí ðñïöõëáêôéêÜ ìüíï ìßá ìÝñá ÷ñüíï, êÜèå 1ç ÄåêÝìâñéïõ.
¸íéùóá èõìü ìå ôïí ßäéï ìïõ ôïí åáõôü, êáíÝíáí Üëëï.
Åãþ Ýöôáéãá áðëÜ.
¼ôáí êÜíåéò óåî ìå ðñïöýëáîç äåí èá êïëëÞóåéò ôßðïôá Üëëùóôå.

Áõôü ôï ïðïßï ìå åíï÷ëåß åßíáé ç ãåëïéüôçôá ôçò êïéíùíßáò ìáò, ôùí êáíáëéþí êáé ôïõ ôýðïõ.
ÂëÝðù Üñèñá ìå ôßôëï "Ôï AIDS ãïõóôÜñåé ôïõò óôñÝéô"¨êáé óêÝöôïìáé üôé äåí õðÜñ÷åé êÜðïéïò íá ôïõò ðåé íá óôáìáôÞóïõí ôá çëßèéá Üñèñá ôïõò êáé íá ìéëÞóïõí óïâáñÜ, ôüóï ãéá ôïí éü, üóï êáé ãéá ôïí óôéãìáôéóìü.
Óôçí åðï÷Þ ðïõ æïýìå, ðïëëïß íïìßæïõí ïôé ôï AIDS ìåôáäßäåôáé ìå Ýíá öéëß óôï ìÜãïõëï, ôï Ý÷ù áêïýóåé, Þ ôï êëáóéêü "ìå ôá êïõíïýðéá".
Ìå ôá êïõíïýðéá ìåôáäßäåôáé ç çëéèéüôçôá êáé ç Üãíïéá. Ôßðïôá Üëëï.
Êáé áõôü ãéáôß ç êïéíÞ ãíþìç äå îÝñåé Þ äå èÝëåé íá îÝñåé ãéá ôï AIDS.

Óå ìéá åðï÷Þ ðïõ ï êüóìïò äåí Ý÷åé íá öÜåé, ðïõ ç ôçëåüñáóç ðáóóÜñåé óêïõðßäéá, áõôü ðïõ ìáò ìÝíåé ùò áðüëáõóç åßíáé íá êÜíïõìå óÝî.
Ïé êõâåñíÞóåéò ìáò äåí åíäéáöÝñïíôáé.
Ðüóïé åðþíõìïé ìå ôïí éü ôï ëÝíå äçìïóßùò?
ÊáíÝíáò,ãéáôß ï êïéíùíéêüò áðïêëåéóìüò êáé ï óôéãìáôéóìüò åßíáé óÞìåñá ôï ìåãáëýôåñï ðñüâëçìá.
Ïé ãéáôñïß êÜíïõí ìïíáäéêÞ äïõëåéÜ, ôïõëÜ÷éóôïí üóïé áó÷ïëïýíôáé ìå ôïí éü, ãéáôß Ý÷ù áêïýóåé ðïëëÜ áðü äéÜöïñåò åéäéêüôçôåò, êõñßùò ïäïíôßáôñïõò.
Ìéáò êáé ôï áíáöÝñù, ï Éáôñéêüò Óýëëïãïò ãéáôß äåí ôïõò ðáßñíåé ôçí Üäåéá íá ôåëåéþíïõìå ìå áõôïýò ôïõò Üó÷åôïõò?

¢ëëïé ðëïõôßæïõí ìå ôïí éü, ëÝãïíôáò üôé åßíáé ìéá ìåãÜëç êïìðßíá ê.ô.ë.
Ìá ôé ëÝíå üëïé?
Ï éüò óêïôþíåé óôçí ÁöñéêÞ áëëÜ êáíåßò äåí åíäéáöÝñåôáé.
Ï ëüãïò åßíáé áðëüò, äåí õðÜñ÷ïõí ÷ñÞìáôá åêåß ãéá ôéò öáñìáêåõôéêÝò åôáéñåßåò.
Íáé ïé êáçìÝíåò, Ý÷ïõí âãÜëåé äéóåêáôïììýñéá êáé èá ôïõò ðÝóåé ï "ìç ðù" íá äþóïõí öôçíÜ öÜñìáêá (Üëëùóôå ðïéïò êáèïñßæåé ôç ôéìÞ ôùí áíôéñåôñïúêþí öáñìÜêùí?).
Áò óôáìáôÞóåé ç óôõãíÞ åêìåôÜëëåõóç ôïõ AIDS áðü ôéò åôáéñåßåò, ç Üãíïéá ôïõ êüóìïõ, ï óôéãìáôéóìüò, ôá ôçëåïðôéêÜ äéêáóôçñéá ôçò êáêéÜò þñáò êáé áò ìáò áöÞóïõí íá æÞóïõìå Þóõ÷á.

Åãþ åñãÜæïìáé ðÜëé, îáíáðÞñá ôç æùÞ óôá ÷Ýñéá ìïõ.

Ç Üãíïéá ðñáãìáôéêÜ óêïôþíåé.
Áò áíáëÜâåé ôï êñÜôïò ôéò åõèýíåò ôïõ êáé íá åëÝã÷åé óå üëá ôá íïóïêïìåßá ôï áßìá êáé ìåôÜ íá êáôáäéêÜæïõí óôá äéêáóôÞñéá ïñïèåôéêïýò ðïõ Ýäùóáí ìïëõóìÝíï áßìá.
Áò êáôáäéêáóôïýí áñ÷éêÜ áõôïß ðïõ âãÜæïõí ôñåëëÜ ëåöôÜ óôçí ðëÜôç ìáò, üóïé êáôáðáôïýí ôá äéêáéùìáôÜ ìáò (üðùò ôá êáíÜëéá ðïõ âãÜæïõí Üó÷åôïõò êáé êÜôé "äçìïóéïãñÜöïõò" ãéá íá êÜíïõí ôçëåïðôéêÜ äéêáóôÞñéá óôéò óêïõðéäïåêðïìðÝò ôïõò).

Æïýìå óå ìéá åðï÷Þ ðïõ áíôß íá êáôáðïëåìÜíå ôïí éü, êáôáðïëåìïýí üóïõò æïõí ìå áõôüí.
ÖôÜíåé ðéá.
¸ëåïò.




... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò